Vyriad, a biotechnology company focused on developing targeted genetic therapies, has announced it has secured $85.0 million in new funding from investors. This significant capital infusion is poised to support the continued advancement of its innovative approach to treating various diseases, particularly in oncology.
Vyriad specializes in engineering viruses, viral vectors, and viral envelope glycoproteins to deliver genes directly to targeted cells. This proprietary targeting technology underpins its work in oncolytic virotherapy, in vivo gene therapies, and gene editing applications. The company's research aims to create the next generation of genetic therapies.
The company is actively engaged in clinical development, testing its oncolytic viruses both as monotherapies and in combination with immuno-oncology drugs. Its Phase 1-2 clinical studies are currently active across multiple cancer types, including non-small cell lung cancer, squamous cell carcinoma of the head and neck, metastatic colorectal cancer, breast cancer, and bladder cancer, among others. Vyriad maintains clinical research collaboration agreements with leading institutions such as Regeneron and Mayo Clinic.
The $85.0 million in raised capital is specifically earmarked to accelerate Vyriad's ongoing research and development efforts. The company plans to strategically deploy these funds to advance its existing clinical pipeline, expand its scientific and operational teams, and further explore the broad potential of its proprietary viral engineering platform. This substantial investment from its backers underscores a strong confidence in Vyriad's foundational technology and its potential to address significant unmet medical needs in the therapeutic landscape.
Looking ahead, Vyriad aims to continue progressing its targeted genetic therapies through clinical trials, with the goal of bringing new treatment options to patients. The company's focus remains on leveraging its viral engineering expertise to develop transformative therapies.
